Role of turmeric in oxidative modulation in end‐stage renal disease patients

Abstract

Oxidative stress is considered as a major player in uremia-associated morbidity and mortality in hemodialysis (HD) patients. The aim of this study was to evaluate the effects of turmeric on oxidative stress markers in HD patients. This study was a prospective and double-blind randomized clinical trial. Fifty HD patients aged 18-60 years were recruited after fulfilling the inclusion criteria. Patients were randomly categorized into 2 groups: trial group received turmeric and control group received placebo for 8 weeks. Each patient in the trial group received turmeric, whereas the control group received starch for the same 8 weeks. Plasma malondialdehyde (MDA), red blood cell (RBC) antioxidant enzyme activities as glutathione peroxidase (GPX), glutathione reductase (GR), and catalase (CAT), cholesterol, high-density lipoprotein-cholesterol, low-density lipoprotein-cholesterol, triglyceride, albumin, and hemoglobin were also measured before and after study. Although MDA level was reduced in both groups, the ratio of decrease was significantly higher in the turmeric group (0.2 vs. 0.1, P = 0.040). Three enzymes of GPX, GR, and CAT levels were increased in both groups; the ratio of increased was significantly higher in the turmeric group for the CAT enzyme (0.73 vs. 0.54; P = 0.02). Also, significant elevation of albumin level in the turmeric group compared with the control group was observed (P = 0.001). Regular ingestion of turmeric reduces plasma MDA and increases RBC CAT activity and plasma albumin levels in HD patients. Turmeric showed no adverse effects.

Role of Dietary Antioxidant Agents in Chronic Kidney Disease

“…Activities of GPx, GR and CAT in red blood cells increased in both groups, the ratio of CAT increment was significantly higher in the trial group. Furthermore, a significant increment in albumin plasma level in the trial group was observed [37]. Therefore, turmeric attenuates oxidative stress and renal damage in hemodialysis patients.…”

“…Moreover, clinical trials have been conducted to evaluate the effect of turmeric on DN [36,37]. In a randomized, double-blind and placebo-controlled study, patients with DN received turmeric (22.1 mg of curcumin, three times a day) for 2 months.…”

“…In another randomized, double-blind, and placebo-controlled study, patients under hemodialysis were randomly divided into control and trial groups [37]. Trial group received turmeric (22.1 mg of curcumin, three times a day) for 8 weeks, whereas control group received starch.…”

The Effect of Polyphenol-Rich Interventions on Cardiovascular Risk Factors in Haemodialysis: A Systematic Review and Meta-Analysis

“…A variety of interventions were investigated including pomegranate juice (standardized to 0.7 mmol/L polyphenols) [ 26 , 36 , 37 ], pomegranate extract (standardized to 600–755 mg gallic acid equivalents), cacao (900 mg cocoa-flavanols) [ 28 ], turmeric (22.1 mg curcumin) [ 27 , 38 ], grape (500 mg total polyphenols) [ 25 ], green tea (455 mg total catechins) [ 39 ], and soy (26–54 mg isoflavones) ( Table 2 ) [ 40 , 41 , 42 , 43 ]. The duration of the study interventions varied from an acute, one day study [ 26 ] to 12 months [ 36 , 37 ].…”

“…In haemodialysis supplementation studies, key vitamins have demonstrated improvements in (non-polyphenol) antioxidant activity, such as Vitamin C [ 22 ] and Vitamin E supplementation [ 23 , 24 ]. While other polyphenol-rich interventions have shown promise to control oxidative stress and ameliorate inflammation in ESKD patients, for example, grape juice powder [ 25 ], pomegranate juice [ 26 ], turmeric [ 27 ], and cocoa flavanols [ 28 ].…”